NASDAQ OMX

Immunicum utser Sharon Longhurst till chef för CMC

Dela

Pressmeddelande

10 oktober 2017

Immunicum AB (publ), First North Premier: (IMMU.ST), ett bioteknikbolag som utvecklar nya immunaktiverande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Sharon Longhurst har utsetts till chef för CMC ( Chemistry, Manufacturing and Controls).

Sharon Longhurst har mer än 15 års erfarenhet av att leda CMC-arbete i både små och medelstora organisationer och kommer senast från Akari Therapeutics där hon var ansvarig för CMC. Hon har tidigare varit farmaciutredare på det brittiska läkemedelsverket MHRA (Medicines & Healthcare Products Regulatory Agency) i London. Sharon ersätter Karin Hoogendoorn som har erbjudits möjligheten att återvända till akademin.

"Sharons erfarenheter från produktion och CMC-strategier inom avancerade terapier kommer att vara viktiga för Immunicums plan att utveckla en kommersiellt fungerande CMC-process för ilixadencel, Immunicums ledande läkemedelskandidat, ", säger Carlos de Sousa, VD för Immunicum. "Vi gläder oss över den karriärmöjlighet Karin fått, och önskar henne lycka till."

"Jag är glad att komma till Immunicum i detta spännande skede i utvecklingen av ilixadencel", säger Sharon Longhurst. "Den potential som ilixadencel har för att stärka immunsystemet vid en rad olika cancerindikationer gör det till ett spännande projekt som kan göra mycket stor skillnad för de som diagnostiseras med cancer. Jag ser verkligen fram emot att bidra till dess fortsatta kliniska framgång genom min erfarenhet av CMC inom området biologiska produkter, framförallt tillverkning och regulatorisk strategi inom cellterapi."

Sharon Longhurst kommer till Immunicum närmast från Akari Therapeutics där hon var Senior CMC Manager med ansvar för alla aspekter av CMC, inklusive klinisk lagerhållning och distribution, för en innovativ biologisk produkt, Coversin. Dessförinnan var Sharon under fem år CMC-konsult vid Parexel Consulting. Mellan 2005 och 2011 var hon farmaciutredare vid enheten för biologi/bioteknik på MHRA i London, där hon arbetade med vetenskaplig rådgivning för Advance Therapy Medicinal Products (ATMPs), såväl nationellt som på EU-nivå, inom cell- och genterapi. Sharon har en doktorsexamen i virologi från University of Warwick i Coventry, Storbritannien.

För ytterligare information kontakta:

Carlos de Sousa, VD, Immunicum
Telefon: +46 (0) 31 41 50 52
E-post: info@immunicum.com

Investor relations, Sverige

Helena Stångberg
Hallvarsson & Halvarsson
Telefon: + 46 (0) 709 71 12 53
E-post: ir@immunicum.com

Mediakontakt 

MacDougall Biomedical Communications
Gretchen Schweitzer eller Stephanie May
Telefon: +49 89 2424 3494 eller + 49 175 571 1562
E-post: ir@immunicum.com  

Bolagets Certified Adviser är Redeye AB
Telefon: +46 (0) 8 545 013 30
www.redeye.se

 

OM IMMUNICUM AB (PUBL)

Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att förbättra överlevnad och livskvaliteten genom att aktivera och förstärka patientens eget immunförsvar för att bekämpa cancern. Företagets ledande produkt, ilixadencel, bestående av pro-inflammatoriska allogena dendritiska celler, har potentialen att bli en grundstomme i modern kombinationsbehandling av ett flertal olika solida tumörformer. Immunicum är grundat och baserat i Sverige och är noterat på Nasdaq First North Premier. www.immunicum.se

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Partnership With FAST Technologies Expands Aptean's European Footprint17.1.2018 21:00Pressmeddelande

ALPHARETTA, Ga., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Aptean, a leading global provider of mission-critical enterprise software solutions, has formed a strategic partnership with FAST Technologies in Northern Ireland. This partnership is an important part of Aptean's growth strategy in the European market, specifically the United Kingdom and the Republic of Ireland. FAST Technologies will sell and support one of Aptean's industry-leading process solutions, Factory Manufacturing Execution System (MES). Process manufacturers use Factory MES to gain real-time visibility into production, operations and quality compliance by adopting a true paperless solution. FAST, a leading provider of industrial automation solutions, is well-established with high-volume manufacturers of retail packaged goods and pharmaceutical products. "We are excited to announce this partnership with Aptean. For many years, we have struggled with an appropriate solution that gives our customers an out-of-the-box experienc

Egyptian Steel recognised in the World Finance 100 guide for 201717.1.2018 15:29Pressmeddelande

LONDON, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Egyptian Steel currently stands as one of the most powerful companies in Egypt. Its prosperity is largely down to the work of founder and CEO, Ahmed Abou Hashima, whose optimistic and bold approach has seen the company go from strength to strength - even in tough conditions. In spite of Egypt's 2011 revolution, which pushed the country through much turmoil, Egyptian Steel was able to take off, having been founded just the year before. Abou Hashima believes that investors shouldn't be put off in times of political uncertainty and economic upheaval. If they are brave, the rewards can be great. And if his organisation's performance is anything to go by, it seems these are wise words; Egyptian Steel's four steel plants now produce 2.3 million tonnes of steel annually. For its outstanding work, Egyptian Steel has been recognised by World Finance in the magazine's World Finance 100 guide, which identifies the world's strongest organisations. Here, co

Investing in Berlin's thriving real estate market17.1.2018 15:05Pressmeddelande

LONDON , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Germany's capital Berlin may be well known as a vibrant tourist destination - the city welcomed 12.7 million visitors last year - but it also offers fantastic investment opportunities. Currently, the real estate market is flourishing, but it is also constantly changing. As such, investors will find that a little market knowledge goes a long way. In 2018, the trend towards renting out furnished apartments looks set to continue, with renovated properties achieving a high sell-on value. Locations will also remain a key factor in determining property prices. In Berlin, real estate buyers will find that high-demand areas like Mitte, Prenzlauer Berg and Friedrichshain offer solid opportunities for return on investment (ROI). Alongside Berlin, other cities in former-East Germany are proving increasingly enticing to real estate developers. Leipzig, for example, has a thriving student population and good job prospects as a result of investment from Por

Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar17.1.2018 14:12Pressmeddelande

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will host a webinar on Thursday, January 18, 2018 at 10 am EST (3pm BST/UK), presented by renowned immunologist, Dr. Jayant Thatte. Dr. Thatte will review currently available humanized models and describe innovative applications for preclinical immuno-oncology research. The evaluation of immunotherapeutics is hindered by a lack of preclinical oncology models that exhibit functional human immunity. To overcome this obstacle, Crown Bioscience uses cutting-edge humanization protocols to develop innovative research solutions with reconstituted, functional human immune components. These humanized models can be combined with human cancer cell lines or patient-derived xenograft (PDX) mo

Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease17.1.2018 14:00Pressmeddelande

NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients, industry and investors to support user-driven innovation, is partnering with UnitedHealth Group (NYSE:UNH) to launch an innovation challenge featuring new businesses and products aimed at treating inflammatory bowel disease (IBD). According to the Centers of Disease Control and Prevention, up to 1.3 million people in the United States are affected by IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC). Lyfebulb and UnitedHealth Group will help raise awareness for the conditions and stimulate user-driven innovation. By linking entrepreneurs with representatives from UnitedHealth Group and Lyfebulb, the partnership will spotlight the entrepreneurs' efforts and ideas, and provide professional discussion, direction and inspiration. The innovation challenge, to take place in the spring and summer of 2018, will be open to entrepreneurs living

Colliers Launches Real Estate Technology Accelerator With Techstars17.1.2018 13:30Pressmeddelande

Partnership with Global Technology Investor and Accelerator Leader Highlights Commitment to Real Estate Industry Innovation TORONTO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ:CIGI) and (TSX:CIGI), a global leader in commercial real estate services, today announced the launch of the Colliers Proptech Accelerator powered by Techstars. "Disruptive changes in technology, evolving demographics, fierce global competition and increased connectivity are factors impacting all industries," said Dylan Taylor, Colliers President & COO. "And the commercial real estate industry is no exception. Colliers sees this as an opportunity and is committed to being the most enterprising company in our industry by developing innovative and value enhancing services for our clients and professionals. Partnering with Techstars allows us to harness the best and brightest in operating technology accelerators and selectively evaluate and invest in new technologies. The new Colliers

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum